Table 3.
Risk factors for positive DVT or SVT at one-week follow-up.
| Negative US N = 42 | Positive US N = 12 | P | |
|---|---|---|---|
| Demographic characteristics | |||
| Male, N (%) | 28 (33.3) | 6 (50.0) | 0.292 |
| Female, N (%) | 14 (66.7) | 6 (50.0) | 0.292 |
| Age, years (SD) | 67.3 (13.0) | 65.0 (21.2) | 0.632 |
| Risk factors | |||
| Thrombophilia, N | 0 | 1 | – |
| Varicose veins, N (%) | 19 (46.3) | 5 (41.7) | 0.775 |
| Antineoplastic treatment/oral contraception, N (%) | 3 (7.3) | 0 | 1.000 |
| Personal history of VTE, N (%) | 5 (12.2) | 2 (16.7) | 0.687 |
| Anticoagulant treatment at inclusion, N (%) | 2 (4.8) | 0 | 0.743 |
| Treated with anti-platelet therapy at inclusion, N (%) | 7 (16.7) | 3 (25) | 0.512 |
| Recent immobilization, N (%) | 12 (28.6) | 4 (33.3) | 0.750 |
| Family history of VTE, N (%) | 2 (4.8) | 1 (8.3) | 0.634 |
| Active cancer, N (%) | 10 (24.4) | 3 (25) | 0.966 |
| Well's score (SD) | 1.5 (0.70) | 1.7 (0.78) | 0.864 |
| Laboratory parameters | |||
| D-dimer, ng/mL (SD) | 1566.2 (3923.6) | 3644.4 (3013.5) | 0.108 |
| Hb, g/dL (SD) | 13.7 (1.5) | 13.1 (1.2) | 0.202 |
| WBC, ×109/L (SD) | 7.8 (2.6) | 8.0 (2.2) | 0.778 |
| Platelets, ×109/L (SD) | 234 (74.1) | 256 (115.6) | 0.446 |
| INR (SD) | 1.01 (0.1) | 1.03 (0.12) | 0.516 |
| aPTT, s. (SD) | 24.8 (3.5) | 24.6 (4.2) | 0.872 |
| Creatinine, mg/dL (SD) | 0.89 (0.34) | 0.96 (0.27) | 0.511 |
| Heparin initiated at ED, N (%) | 19 (45.2%) | 9 (75%) | 0.069 |
aPTT: activated partial thromboplastin time; DVT: deep vein thrombosis; INR: international normalized ratio; SD: standard deviation; SVT: superficial vein thrombosis; VTE: venous thromboembolism; WBC: white blood cells.